A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China (MAP)

AstraZeneca

Status: Begins enrollment in 2 months

Conditions: Non-Small-Cell Lung

Study type: Observational

Funder types: Industry

Identifiers

NCT07316062

D133FR00236

Details and patient eligibility

About

This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.

Full description

The primary objective of this study is to understand the evolution of initial treatment patterns among patients with early-stage (I-III) NSCLC.

Enrollment: 3,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Stage I-III at initial NSCLC diagnosis
• Aged ≥18 years at first diagnosis of NSCLC
• Timeframe of NSCLC diagnosis:

For DE1: diagnosed with NSCLC during the period between May 1st 2025 and December 31st 2025 For DE2: diagnosed with NSCLC during the period between May 1st 2026 and December 31st 2026 For DE3: diagnosed with NSCLC during the period between May 1st 2027 and December 31st 2027

Exclusion criteria

• NSCLC is not the primary cancer diagnosis
• Patients with a recent history of other tumor or concurrent other tumor
• Patients participating in interventional clinical trials at time of initial diagnosis
• Patients with positive pregnancy status at the time of diagnosis